• Michael Wall, Julie Falardeau, William A Fletcher, Robert J Granadier, Byron L Lam, Reid A Longmuir, Anil D Patel, Beau B Bruce, Hua He, Michael P McDermott, and NORDIC Idiopathic Intracranial Hypertension Study Group.
• From the Departments of Neurology and Ophthalmology (M.W.) and Ophthalmology and Visual Sciences (R.A.L.), University of Iowa, Iowa City; Casey Eye Institute (J.F.), Department of Ophthalmology, Oregon Health and Science University, Portland; Department of Clinical Neurosciences (W.A.F.), University of Calgary, Canada; William Beaumont Hospital (R.J.G.), Royal Oak, MI; Bascom Palmer Eye Institute (B.L.L.), University of Miami, FL; Dean A. McGee Eye Institute (A.D.P.), Oklahoma University, College of Medicine, Oklahoma City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; and Department of Biostatistics and Computational Biology (H.H., M.P.M.), University of Rochester, NY. michael-wall@uiowa.edu.
• Neurology. 2015 Sep 1;85(9):799-805.

ObjectivesDetermine potential risk factors for progressive visual field loss in the Idiopathic Intracranial Hypertension Treatment Trial, a randomized placebo-controlled trial of acetazolamide in patients with idiopathic intracranial hypertension and mild visual loss concurrently receiving a low sodium, weight reduction diet.MethodsLogistic regression and classification tree analyses were used to evaluate potential risk factors for protocol-defined treatment failure (>2 dB perimetric mean deviation [PMD] change in patients with baseline PMD -2 to -3.5 dB or >3 dB PMD change with baseline PMD -3.5 to -7 dB).ResultsSeven participants (6 on diet plus placebo) met criteria for treatment failure. The odds ratio for patients with grades III to V papilledema vs those with grades I and II was 8.66 (95% confidence interval [CI] 1.65-∞, p = 0.025). A 1-unit decrease in the number of letters correct on the ETDRS (Early Treatment Diabetic Retinopathy Study) chart at baseline was associated with an increase in the odds of treatment failure by a factor of 1.16 (95% CI 1.04-1.30, p = 0.005). Compared with female participants, the odds ratio for male participants was 26.21 (95% CI 1.61-433.00, p = 0.02). The odds of treatment failure were 10.59 times higher (95% CI 1.63-116.83, p = 0.010) for patients with >30 transient visual obscurations per month vs those with ≤30 per month.ConclusionsMale patients, those with high-grade papilledema, and those with decreased visual acuity at baseline were more likely to experience treatment failure. All but one of these patients were treated with diet alone. These patients should be monitored closely and be considered for aggressive treatment of their idiopathic intracranial hypertension.© 2015 American Academy of Neurology.

33 keywords...

hide…